Sarcoma
(I.R.I.S.) Servier / CL3-95031-007
Official Title: A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen
Study Purpose: To assess how well the drug Ivosidenib works against chondrosarcoma
Status:
Recruiting